<DOC>
	<DOCNO>NCT00632736</DOCNO>
	<brief_summary>To evaluate safety profile ropinirole XL long-term treatment subject early advance Parkinson 's disease</brief_summary>
	<brief_title>An Open-label Continuation Study Evaluating Long-term Safety Extended Release Ropinirole XL ( Formerly CR ) Parkinson '' Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<criteria>A subject eligible inclusion study follow criterion apply : Subjects must complete REQUIP study 165 168 , must complete least 12 week randomise treatment study 169 ( must complete oneweek titration end treatment/early withdrawal ) . Subjects must break medication complete feeder study ( include titration phase study 168 169 ) begin treatment study 248 . Women childbearing potential must practice clinically accept method contraception study one month follow completion study . Acceptable contraceptive method include oral contraception , surgical sterilization , intrauterine device ( IUD ) , diaphragm IN ADDITION spermicidal foam condom male partner , systemic contraception ( e.g . Norplant System ) . Provide write informed consent study . Be willing able comply study procedure . A subject eligible inclusion study follow criterion apply : Patients ongoing clinically significant adverse event end `` feeder '' study . Subjects severe , clinically significant condition ( ) Parkinson 's disease , opinion investigator , would render subject unsuitable study ( e.g. , psychiatric , hematological , renal , hepatic , endocrinology , neurological ( Parkinson 's disease ) , cardiovascular , active malignancy ( basal cell carcinoma ) . Subjects clinically significant abnormality Laboratory ECG test end feeder study ( REQUIP study 165 , 168 169 ) . Subjects severe dizziness fainting due postural hypotension stand . Withdrawal , introduction , change dose hormone replacement therapy and/or drug know substantially inhibit cytochrome P 450 1A2 ( CYP1A2 [ e.g . ciprofloxacin , fluvoxamine , cimetidine , ethinyloestradiol ] ) induce CYP1A2 ( e.g . tobacco , omeprazole ) within 7 day prior enrolment . Subjects already chronic therapy agent may enrol dos must remain stable 7 day prior enrolment end treatment period . Women pregnant breastfeeding . Use investigational drug throughout treatment period .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ropinirole XL</keyword>
	<keyword>REQUIP</keyword>
	<keyword>Parkinson 's disease</keyword>
	<keyword>long term safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>ropinirole CR</keyword>
	<keyword>ropinirole IR</keyword>
	<keyword>open-label</keyword>
</DOC>